Literature DB >> 18634857

The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine.

P Marquez1, J Borse, A T Nguyen, A Hamid, K Lutfy.   

Abstract

We have previously shown that the ability of buprenorphine to activate the opioid receptor-like (ORL1) receptor compromises its antinociceptive effect. Furthermore, morphine has been shown to alter the level of orphanin FQ/nociceptin (OFQ/N), the endogenous ligand of the ORL1 receptor, raising the possibility that the endogenous OFQ/N/ORL1 receptor system may be involved in the actions of these opioids. Thus, using mice lacking the ORL1 receptor and their wild-type littermates, the present study assessed the role of the ORL1 receptor in psychomotor stimulant and rewarding actions of buprenorphine and morphine. Morphine (5, 10 mg/kg) dose-dependently increased motor activity and induced conditioned place preference. However, the magnitude of each response was comparable for the mutant mice and their wild-type littermates. In contrast, buprenorphine (1 mg/kg) induced greater motor stimulation in ORL1 receptor knockout mice as compared with their wild-type littermates. Further, single conditioning with buprenorphine (3 mg/kg) induced place preference in mutant mice but not in their wild-type littermates. The results of binding assay showed that buprenorphine concentration-dependently (0-1000 nM) displaced specific binding of [(3)H]-OFQ/N in brain membrane of wild-type mice. Together, the present results suggest that the ability of buprenorphine to interact with the ORL1 receptor modulates its acute motor stimulatory and rewarding effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18634857      PMCID: PMC2631239          DOI: 10.1016/j.neuroscience.2008.06.027

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  43 in total

Review 1.  Conditioned place preference: what does it add to our preclinical understanding of drug reward?

Authors:  M T Bardo; R A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

2.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

3.  Heroin-induced locomotion and mesolimbic dopamine release is unchanged in mice lacking the ORL.1 receptor gene.

Authors:  Niall P Murphy; Hoa A Lam; Zhenping Chen; John E Pintar; Nigel T Maidment
Journal:  Brain Res       Date:  2002-10-25       Impact factor: 3.252

4.  Dimerization of morphine and orphanin FQ/nociceptin receptors: generation of a novel opioid receptor subtype.

Authors:  Ying-Xian Pan; Elizabeth Bolan; Gavril W Pasternak
Journal:  Biochem Biophys Res Commun       Date:  2002-09-27       Impact factor: 3.575

5.  Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.

Authors:  P Bloms-Funke; C Gillen; A J Schuettler; S Wnendt
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

6.  Delta opioid antagonist effects of buprenorphine in rhesus monkeys.

Authors:  S S Negus; J M Bidlack; N K Mello; M S Furness; K C Rice; M R Brandt
Journal:  Behav Pharmacol       Date:  2002-11       Impact factor: 2.293

7.  Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors.

Authors:  J E Hawkinson; M Acosta-Burruel; S A Espitia
Journal:  Eur J Pharmacol       Date:  2000-02-18       Impact factor: 4.432

Review 8.  The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.

Authors:  J S Mogil; G W Pasternak
Journal:  Pharmacol Rev       Date:  2001-09       Impact factor: 25.468

Review 9.  Buprenorphine: how to use it right.

Authors:  Rolley E Johnson; Eric C Strain; Leslie Amass
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

10.  Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.

Authors:  Kabirullah Lutfy; Shoshana Eitan; Camron D Bryant; Yu C Yang; Nazli Saliminejad; Wendy Walwyn; Brigitte L Kieffer; Hiroshi Takeshima; F Ivy Carroll; Nigel T Maidment; Christopher J Evans
Journal:  J Neurosci       Date:  2003-11-12       Impact factor: 6.167

View more
  9 in total

1.  Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Authors:  Michael S Virk; Seksiri Arttamangkul; William T Birdsong; John T Williams
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

Review 2.  The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.

Authors:  Nurulain T Zaveri
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  Analgesic efficacy of buprenorphine in the presence of high levels of SDF-1α/CXCL12 in the brain.

Authors:  Khalid Benamar; Jonathan Palma; Alan Cowan; Ellen B Geller; Martin W Adler
Journal:  Drug Alcohol Depend       Date:  2010-11-26       Impact factor: 4.492

Review 4.  Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.

Authors:  Jia-Jia Zhang; Chang-Geng Song; Ji-Min Dai; Ling Li; Xiang-Min Yang; Zhi-Nan Chen
Journal:  MedComm (2020)       Date:  2022-06-22

5.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

6.  Combined scopolamine and ethanol treatment results in a locomotor stimulant response suggestive of synergism that is not blocked by dopamine receptor antagonists.

Authors:  Angela C Scibelli; Tamara J Phillips
Journal:  Alcohol Clin Exp Res       Date:  2008-12-13       Impact factor: 3.455

Review 7.  The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Authors:  Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo
Journal:  Pharmacol Ther       Date:  2013-11-01       Impact factor: 12.310

Review 8.  Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics.

Authors:  Massimo Ubaldi; Nazzareno Cannella; Roberto Ciccocioppo
Journal:  Prog Brain Res       Date:  2015-11-26       Impact factor: 2.453

Review 9.  A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain.

Authors:  Jeffrey Gudin; Jeffrey Fudin
Journal:  Pain Ther       Date:  2020-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.